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There has been considerable historical interest in the concept of a specialist T-cell subset which suppresses over-zealous or inappropriate T-cell responses. However, it was not until the discovery that CD4
+ CD25 + T-cells had suppressive capabilities both in vitro and in vivo that this concept regained credibility and developed into one of the most active research areas in immunology today. The notion that in healthy individuals there is a subset of T reg -cells (regulatory T-cells) involved in 'policing' the immune system has led to the intensive exploration of the role of this subset in disease resulting in a number of studies concluding that a quantitative or qualitative decline in T reg -cells is an important part of the breakdown in self-tolerance leading to the development of autoimmune diseases. Although T reg -cells have subsequently been widely postulated to represent a potential immunotherapy option for patients with autoimmune disease, several studies of autoimmune disorders have demonstrated high numbers of T reg -cells in inflamed tissue. The present review highlights the need to consider a range of other factors which may be impairing T reg -cell function when considering the mechanisms involved in the breakdown of self-tolerance rather than focussing on intrinsic T reg -cell factors.
TOLERANCE AND REGULATORY T-CELLS
As well as being able to recognize pathogens, it is crucial that the adaptive immune response is tolerant of self-antigens. In order to facilitate this, lymphocyte tolerance mechanisms have evolved and can be divided into two broad categories. Central tolerance involves the censoring of self-reactive immature B-and T-cells as they differentiate in the bone marrow and thymus respectively [1] . Conversely, peripheral tolerance relates to mature Band T-cells, outside the bone marrow and thymus, when they are circulating in the blood, lymph and secondary lymphoid tissue, or after they have accessed other organs in response to certain stimuli. The relative importance of central compared with peripheral tolerance mechanisms has been widely debated for a number of years. Although this debate is unlikely to be settled for some time, it is clear that, although central tolerance is important, it is not absolute since most individuals harbour autoreactive cells [2] . This clearly demonstrates that peripheral mechanisms are also crucially important in the maintenance of self-tolerance. Peripheral tolerance can be achieved by a number of different processes including immunological 'ignorance', anergy, immune deviation and apopotosis. Interest in peripheral tolerance has greatly increased in the last decade, principally because of the growing appreciation of the crucial role T reg -cells (regulatory T-cells) play in maintenance of self-tolerance [1] .
Figure 1 CD4 + T-cell lineages
Naturally occurring CD4 + Foxp3 + T reg -cells are part of a diverse group of CD4 + subsets which also include effector Th1, Th2 and Th17 lineages. The cytokines in red are key molecules in the development of Th1, Th2, Th17 and T reg -cell (Treg) lineages. The cytokines in blue are some of the key molecules produced by the various CD4 + lineages.
There has been considerable historical interest in the concept of the existence of a specialist T-cell subset which suppresses over-zealous or inappropriate T-cell responses. For example, neonatal thymectomy leads to the spontaneous development of autoimmune diseases including gastritis and thyroiditis [3, 4] . In addition, transfer of CD4 + T-cells from MHC-compatible mice effectively prevented the onset of diabetes [5] ; however, it proved difficult to isolate the proposed suppressor population from pathogenic CD4 + T-cells and it has been only in the last few years that the phenotype of T reg -cells have been characterized, which has allowed their role in the development of a range of pathologies to be extensively studied ( Figure 1 ) [6] .
By the definition that T reg -cells are T-cells with an immunosuppressive phenotype, several different types of T reg -cells have been described including naturally arising CD4 + CD25 + T reg -cells, IL (interleukin)-10-secreting Tr1 cells, TGF-β (transforming growth factor-β)-secreting Th3 cells, CD8
+ CD28 − T-cells, CD8 + CD122 + T-cells, γ δ T-cells and NK (natural killer) T-cells ( Figure 1 ) [7] . Some T reg -cell populations are naturally produced in the immune system as functionally distinct populations, termed natural T reg -cells, whereas others are adaptively induced from naïve T-cells as a consequence of a particular mode of antigen exposure, especially in a particular cytokine milieu, and are called adaptive T regcells [8, 9] . However, among the several types of T reg -cells reported, naturally occurring CD4
(where Foxp3 is forkhead box p3) T-cells are the main focus of research, following numerous examples of their importance in the maintenance of self-tolerance, and will be the focus of the present review [10] . The renewed interest in T reg -cells stemmed from seminal observations by Sakaguchi and co-workers [11, 12] in the mid-1990s. They observed that inoculation of T-cell-deficient BALB/c mice with CD4 + T-cells depleted of CD25 + cells caused a variety of autoimmune diseases including gastritis, insulitis and thyroiditis, but that transferring CD4 + CD25 + T-cells could prevent autoimmune pathology [11] . These observations were linked to earlier studies which demonstrated that thymectomy of 3-day-old mice caused widespread autoimmunity by demonstrating that CD4 + CD25 + T-cells begin to appear in the periphery 3 days after birth, and that inoculation of CD4 + CD25 + T-cells after thymectomy prevents the development of autoimmunity [12] . Consequently, CD4
+ CD25 + T-cells became known as naturally occurring T reg -cells and have become an important paradigm in our current understanding of the development of autoimmunity.
Although CD25 is an important marker of T reg -cells and is widely used to purify T reg -cells ex vivo, it is important to acknowledge that no particular cell-surface marker is uniquely associated with T reg -cells, and CD25 can be up-regulated in activated conventional T-cells. [10] . Because of the limitations of CD25 as a marker of T reg -cells, an extensive search of other specific markers of T reg -cells was undertaken which, ultimately, identified Foxp3 as the 'master controller' of T reg -cell function [13] [14] [15] . Foxp3 + cells have subsequently been shown to be crucial in preventing autoimmunity through life [16] .
It is important to acknowledge that, although Foxp3 has become a widely accepted marker for T reg -cells in the mouse, the situation is less straight-forward in humans [17] . Although humans with IPEX (immunodysregulation, polyendocrinopathy and enteropathy, X-linked syndrome) lack Foxp3 + cells and subsequently develop severe autoimmune disease [14, 15] , it is becoming increasingly apparent that human activated T-cells can also express Foxp3 in cells which lack regulatory function [18, 19] , and induction of Foxp3 ex vivo does not confer a regulatory phenotype [20] . Consequently, one of the greatest challenges in the field of peripheral tolerance is to further understand the differences and similarities between human and murine T reg -cells.
The mode of action of CD4 + Foxp3 + cells is an area of intense scientific study which has recently been grouped into four basic models of action, namely suppression by inhibitory cytokines, suppression by cytolysis, suppression by metabolic disruption and suppression by modulation of DC (dendritic cell) maturation or function (Figure 2 ), which have been reviewed in detail elsewhere (see references [17, 21] ). CD4 + Foxp3 + T reg -cells can suppress the proliferation and cytokine production of effector T-cells through production of inhibitory cytokines, most notably IL-10 and TGF-β. A role for T regcell-produced IL-35 has also been recently postulated [22] . Suppression by cytolysis of effector T-cell killing by T reg -cells through the release of granzyme B and perforin has also been reported [23, 24] . A third mode of action is suppression by metabolic disruption such as cytokinedeprivation-mediated apoptosis of effector CD4
+ T-cells [25] , and intracellular or extracellular release of adenosine nucleosides which leads to suppression of effector T-cells [26, 27] . A fourth method of T reg -cell-mediated suppression is by modulating the maturation and/or function of DCs. For example, imaging studies have also shown that T reg -cells can modulate effector T-cell function without forming stable interactions with effector T-cells. Using two photon laser-scanning microscopy, Bluestone and co-workers [28] demonstrated that islet-specific T regcells clustered around antigen-bearing DCs in the PLNs (peripheral lymph nodes) of prediabetic NOD (nonobese diabetic) mice, thereby blocking the ability of DCs to trigger effector T-cell proliferation and differentiation [28] . The mechanism(s) involved in this process is incompletely resolved, although T reg -cells have been shown to up-regulate the activity of IDO (indolamine 2,3-dioxygenase) in DCs which results in tryptophan deprivation leading to effector T-cell apoptosis [29] . There is still much to be understood about how natural T reg -cells exert their suppressive function both in vitro and in vivo, and this is an area of intense research.
REGULATORY T-CELLS AND EXPERIMENTAL MODELS OF AUTOIMMUNITY Quantitative changes in T reg -cells
As T reg -cells have been clearly demonstrated to have an important role in the maintenance of tolerance, inevitably their role in the development of pathology has been intensively explored previously [30] [31] [32] . This section of the review will focus on discussing the numerous studies which have been undertaken on quantitative and qualitative changes in T reg -cells in the model of Type 1 diabetes, the NOD mouse, which is widely considered to be one of the best murine models of spontaneous autoimmunity [33] . In NOD mice, insulitis develops from 3 to 4 weeks of age and is well established by 6-8 weeks of age. Progression to overt diabetes occurs in approx. 80 % of females between 12 and 30 weeks of age [34, 35] . Several studies have argued that there are no abnormalities in T reg -cell frequency in the NOD
Figure 2 Mode of action of T reg -cells
The CD4
+ Foxp3 + T reg -cell mode of action has been recently classified into four basic modes of action, namely suppression by inhibitory cytokines, suppression by cytolysis, suppression by metabolic disruption and suppression by modulation of DC maturation or function [17] . IDO, indoleamine 2,3-dioxygenase; Treg, T reg -cell; Teff, effector T-cell.
mouse, including Berzins et al. [36] who found that the proportion of CD4 + T-cells expressing CD25 in the spleen, lymph nodes and pancreatic draining lymph nodes was similar in NOD mice to three other non-autoimmune-prone mouse strains. Gregori et al. [37] reported no differences in the frequency and in the total number of CD4 + CD25 + cells in the spleen or PLNs of 8-week-old NOD mice compared with 16-week-old NOD mice [37] . Additional support for the notion that diabetic mice do not have a decline in the frequency of T reg -cells comes from the observation made by You et al. [38] who found that CD4 + CD25 + T-cells from diabetic NOD mice expressed higher levels of Foxp3 mRNA compared with those from 6-week-old NOD mice. In contrast, other studies have shown both an age-related decline in T regcells in NOD mice, as well as a reduced total number of T reg -cells compared with non-autoimmune-prone strains of mice. For example, Pop et al. [39] demonstrated that the frequency of Foxp3-expressing CD25 + CD62L hi cells decline with age in the pancreatic draining lymph nodes of NOD, but not C57BL/6, mice, and Wu et al. [40] noted that the total number of splenic CD4 + CD25 + cells was lower in NOD mice compared with age-matched Balb/c mice. In addition, Alard et al. [41] found that the percentage of CD4 + CD25 + T-cells was lower in the spleens and lymph nodes of 9-week-old female NOD mice compared with age-matched C57BL/6 mice [41] . One of the major difficulties in drawing conclusions about the various studies on T reg -cell quantification is that a range of approaches have been taken to assess T regcell populations. Arguably, the most appropriate way to quantify T reg -cells is through assessment of Foxp3 protein and, in a recent study which investigated the number of CD4 + T-cells which were Foxp3 + , there was no evidence of a quantitative decline in T reg -cell numbers in the spleen, pancreatic draining lymph nodes or the pancreas itself with age or even after the onset of diabetes [42] . Furthermore, a recent study found evidence of enhanced thymic selection of Foxp3 + T reg -cells in NOD mice [43] .
Qualitative changes in T reg -cells in vitro
A number of studies have also investigated whether there is a decline in NOD T reg -cell function in vitro using a variety of in vitro suppression assays to study changes in T reg -cell function over time or following onset of disease. For example, Gregori et al. [37] used an alloantigen-driven in vitro assay to investigate whether T reg -cell function declines with age in NOD mice [37] . [38] . Further support for the notion that there is an age-related decline in T reg -cell function is presented by Pop et al. [39] who showed that CD4
+ CD25 + CD62L hi T-cells from the PLNs of 16-week-old NOD mice were less suppressive in vitro than CD4
+ CD25 + CD62L hi T-cells from 4-week-old NOD mice [39] . However, other investigators have failed to replicate the finding that there is a qualitative decline in NOD T reg -cell function in vitro. A previous study [41] has shown that splenic CD4 + CD25 + T-cells from diabetic NOD mice were as effective as CD4
+ CD25 + T-cells from non-diabetic NOD mice in suppressing the proliferation of CD4
+ CD25 − T-cells or production of IFN-γ (interferon-γ ) in vitro. This observation was replicated when the CD4 + CD25 + and CD4 + CD25 − T-cells were isolated from the pancreatic draining lymph node [42] .
Qualitative changes in T reg -cell function in vivo
Arguably, the most objective way to assess the in vivo function of T reg -cells is by co-transfers with a standardized dose of effector cells into NOD/SCID (severe combined immunodeficiency) recipients and this approach has been adopted by a number of investigators. For example, Gregori et al. [37] found that CD4 + CD25 + T-cells from 8-week-old, but not 16-week-old, NOD mice could suppress the transfer of disease by 16-week-old CD25-depleted splenocytes to NOD/SCID recipients. In addition, Gregg et al. [44] reported that CD4 + CD25 + cells from 6-week-old, but not 8-week-old, NOD mice could inhibit the transfer of disease by diabetic splenocytes to NOD/SCID recipients. Using BDC2.5NOD CD4 + Tcells as effectors, Pop et al. [39] found that CD4 + CD25 + T-cells isolated from the PLNs of 4-week-old, but not 8-week-old or 16-week-old, NOD mice were able to suppress the transfer of disease to NOD/SCID recipients. However, these experiments are again difficult to interpret owing to the presence of contaminating non-Foxp3 + cells which are invariably present when CD25 expression is used to positively select the T reg -cell population [42] .
Changes in T reg -cell function following therapeutic intervention in NOD mice
Some of the most interesting insights into T reg -cell function in NOD mice come from studies which have shown that therapies which can successfully treat diabetes in NOD mice do so by restoring and/or enhancing the functional capabilities of T reg -cells. For example, in diabetic NOD mice which were reverted to a normoglycaemic state following administration of an anti-CD3 antibody, the proportion of CD4 + CD25 + T-cells significantly increased following anti-CD3 treatment of diabetic NOD mice. In addition, the suppressive capacity of CD4 + CD25 + T-cells in vitro also increased following treatment [45] . The suppressive capacity of the CD4 + CD25 + T-cells could be reversed if an antibody to TGF-β was added to the co-cultures, and that coadministration of an anti-TGF-β antibody together with anti-CD3 antibody prevented the induction of remission in diabetic NOD mice. Taken together, these observations indicate a central role of TGF-β in the tolerogenic effect of anti-CD3 antibodies [45] .
REGULATORY T-CELLS AND CLINICAL AUTOIMMUNITY
As well as exploring the role of T reg -cells in experimental models of autoimmunity there have been a large number of studies which have investigated T reg -cell function in human patients with spontaneous autoimmune diseases [46] . For example, one of the earliest reports on defective T reg -cell function in human diabetes showed that the proportion of CD4 + T-cells which expressed CD25 was significantly lower in both newly diagnosed and long-standing patients with Type 1 diabetes compared with normal controls and patients with Type 2 diabetes [47] . However, the observation that fewer CD4 + cells expressed CD25 was not replicated in three subsequent studies [48] [49] [50] . In addition, Tsutsumi et al. [50] found that the expression levels of Foxp3 based on RT (reverse transcription)-PCR was not significantly different in patients with Type 1 diabetes and healthy controls. Nonetheless, both Lindley et al. [48] and Brusko et al. [49] found qualitative differences in CD4 + CD25 + T-cells in patients with Type 1 diabetes compared with normal controls. Both studies showed that, although the proportions of CD4 + CD25 + T-cells are normal in patients with recent-onset Type 1 diabetes, the ability of these cells to suppress T-cell proliferation and IFN-γ production during in vitro co-cultures was markedly reduced compared with control subjects [48, 49] .
The finding of defects in T reg -cells in human patients with autoimmune disorders is not limited to diabetes. Kriegel et al. [51] found that the suppressive capacity of CD4 + CD25 + T-cells in co-cultures with CD4 + CD25 − T-cells and OKT3 (also called muromonab) or PHA (phytohaemagglutinin) was impaired in patients with APS-II (autoimmune polyglandular syndrome type II) [51] . Furthermore, T reg -cells from normal donors could suppress responders from patients with APS-II, whereas APS-II T reg -cells could not suppress CD4
+ CD25 − T-cells from normal donors, indicating that the failure of APS-II T reg -cells to suppress was due to a defect in the T reg -cells rather than increased resistance of APS-II responders to T reg -cell-mediated suppression. Similar findings were made in patients with myasthenia gravis; in contrast with normal patients,
CD4
+ CD25 + thymocytes from patients with myasthenia gravis were unable to suppress the proliferative response of CD4 + CD25 − thymocytes to allogenic stimulation. The amount of Foxp3 mRNA from patients was reduced 2-fold compared with young adult and newborn CD4 + CD25 + thymocytes [52] . CD4 + CD25 hi T-cells from patients with multiple sclerosis were found to suppress CD4 + CD25 − T-cell proliferation and IFN-γ production less effectively than CD4 + CD25 hi cells from normal donors co-cultured with CD4 + CD25 − T-cells and anti-CD3 antibody [53] . Finally, qualitative and/or quantitative differences in CD4 + CD25 + T-cells were also obtained in patients with psoriasis, autoimmune liver disease and systemic lupus erythematosus [54] [55] [56] .
In addition, reversal of compromised T reg -cell function has been demonstrated in humans with rheumatoid arthritis who experienced clinical improvement following anti-TNF-α therapy [57] . CD4 + CD25 + T-cells isolated from the peripheral blood of both healthy controls and patients with active rheumatoid arthritis were able to suppress the in vitro proliferation of effectors but, unlike CD4 + CD25 + from healthy controls, those from patients with active rheumatoid arthritis were unable to suppress the production of pro-inflammatory cytokines. However, the ability to suppress production of proinflammatory cytokines in vitro was restored following anti-TNF-α therapy. In addition, the proportion of CD4 + CD25 hi T-cells increased in patients who responded to anti-TNF-α therapy compared with pretreatment, as well as compared with non-responders. Subsequent studies suggested that anti-TNF-α therapy generates a newly differentiated population of T reg -cells which compensates for the defective T reg -cells present in patients with rheumatoid arthritis [58] .
However, although there is considerable evidence that there is an in vitro decline in the function of T reg -cells isolated from patients with autoimmune disease, this is not an absolute consensus since some authors have found little change in T reg -cell function in patients with autoimmune diseases. For example, Putnam et al. [59] found that, unlike previous reports, CD4
+ CD25 hi T-cells from patients with Type 1 diabetes were able to suppress the in vitro proliferation of CD4 + CD25 − T-cells to a similar extent as CD4 + CD25 hi T-cells isolated from healthy controls. Arguably the most definitive work in this area to date, which used expression of Foxp3 + protein to identify T reg -cells, found no evidence of a quantitative decline in T reg -cells in patients with Type 1 diabetes [60] .
A similar lack of decline in T reg -cell numbers has been widely observed in patients with autoimmune arthritis. The proportion of peripheral CD4
+ T-cells which expressed CD25 was found to be similar or higher in patients with rheumatoid arthritis or juvenile idiopathic arthritis compared with normal controls in two studies [61, 62] , but in another study was found to be lower [63] . An increase in the numbers of CD4 + CD25 + T-cells in the synovial fluid of affected joints compared with the peripheral blood was also observed in several studies [61, [63] [64] [65] [66] [67] [68] [69] [70] . Furthermore, the synovial CD4 + CD25 + T-cells were able to suppress the proliferation of CD4 + CD25 − T-cells in vitro and/or suppress the production of pro-inflammatory cytokines [61, 63, 65, 66, 68] . In addition, the proportion of CD4 + CD25 bright T-cells were higher in the peripheral blood and synovial fluid of patients with a benign self-remitting episode of juvenile idiopathic arthritis than in patients with extended oligoarticular disease, indicating that T reg -cells may play a role in determining the clinical course of disease [71] . A particularly interesting study demonstrated that, in patients with juvenile idiopathic arthritis, CD4
+ CD25
+ T-cells were present at a higher frequency in joints than in peripheral blood, were suppressive in vitro and that the T reg -cell subset CD4 + CD25 + CD27 + was particularly effective at reducing CD4 + CD25 − T-cell proliferation in vitro [68] . This study also showed that IL-7 and IL-15 were present in the synovial fluid of affected patients and that these cytokines, when added to in vitro T reg -cell assays, abrogated the suppressive abilities of T reg -cells leading to the conclusion that inflammatory cytokines present in inflamed tissue can interfere with T reg -cell function. Other groups have also observed that IL-7 can disrupt suppression mediated by CD4 + CD25 + isolated from patients with rheumatoid arthritis in vitro [64] .
Additional reports from patients with ulcerative colitis, primary Sjogren's syndrome and autoimmune thyroid disease further highlight the lack of consensus on the role of T reg -cells in autoimmune pathology in humans; peripheral CD4 + CD25 + T-cells from patients with primary Sjogren's syndrome were not lower than age-matched controls and were effective at suppressing the in vitro proliferation of effectors [72] . Colonic CD4 + CD25 + T-cells from patients with ulcerative colitis were able to suppress the in vitro proliferation of colonic effector T-cells and the proportion of T reg -cells increased with disease activity leading to the suggestion "that their suppressive capacity was being influenced by the in vivo environment" [73] . It has subsequently been shown that patients with ulcerative colitis have significantly increased frequencies of CD25 + and Foxp3 + lymphocytes in the lamina propria [74] . There was a significantly higher number of CD4 + Foxp3 + T-cells in the peripheral blood of patients with autoimmune thyroid disease than normal controls and there was no difference in the proportion of CD4 + Foxp3 + T-cells in the peripheral blood compared with thyroid disease in patients with autoimmune thyroid disease [75] . Interestingly, the reported dramatic effects of the anti-TNF-α drug infliximab on T reg -cell function and number [57] was not replicated in a previous study of the fully human anti-TNF-α antibody adalimumab, which found that this drug had only a modest and transient effect on T reg -cells [76] . Collectively, these studies clearly indicate that a simple imbalance of T reg -cells to effector T-cells is not consistently observed at the site of disease in humans with autoimmune diseases.
IS THERE A ROLE FOR REGULATORY T-CELLS IN THE CLINIC?
The absence of consensus on T reg -cell qualitative and quantitative changes in autoimmune diseases has not diminished enthusiasm in developing clinical therapies which 'reset the balance' between effectors and T reg -cells by administering ex vivo-expanded antigen-specific T regcells to patients with autoimmune conditions [77] [78] [79] [80] [81] . Considerable progress has been made in this field over the past few years; for example, Bluestone and co-workers [82] initially developed a strategy of expanding antigenspecific T reg -cells from NOD mice by in vitro culture with anti-CD3 antibody, anti-CD28 antibody and IL-2. They developed these observations further by expanding antigen-specific T reg -cells from NOD mice in vitro using IL-2 and beads coated with anti-CD28 antibody and recombinant islet peptide-MHC class II complexes [83] . The expanded antigen-specific T reg -cells were capable of bystander suppression both in vitro and in vivo and isletpeptide-specific T reg -cells were more efficient than polyclonal T reg -cells in suppressing autoimmune diabetes.
However, the general approach of developing strategies to replace T reg -cells in patients with autoimmune diseases neglects to acknowledge the wealth of data that indicates that T reg -cells are present, often in considerable numbers, at the site of autoimmunity. Therefore one of the key challenges facing immunologists is to understanding why autoimmunity develops even if T reg -cells are present in abundance at the site of inflammation, since a deeper understanding of this paradox may open up novel therapeutic avenues. As previously discussed, in vitro studies of CD4 + CD25 + Tcells from patients with rheumatoid arthritis have shown that cytokines, most notably IL-7, can interfere with T regcell-mediated suppression [64, 68] . Support for the notion that cytokines can interfere with T reg -cell function comes from recent work on the role of myelin-specific T reg -cells in EAE (experimental autoimmune encephalomyelitis) [84] . It was shown that, as soon as autoimmunity had been triggered, T reg -cells were present in the target tissue in a favourable T reg -cell/effector T-cell ratio at the onset of disease, but they still could not control the expansion and function of pathogenic effector T-cells. This was shown to be not due to an insufficient suppressive capacity of CNS (central nervous system) T reg -cells, but because of the intrinsic resistance of CNS-derived effector T-cells to suppression, which was associated with their production of IL-6 and TNF. This study is one of the most compelling to date to indicate that, in order for T reg -cells to exert their suppressive function in established autoimmune disease, the local inflammatory cytokine milieu in the target tissue needs to be controlled [84] .
The present review briefly highlights the remarkable advances in our understanding of T reg -cells in recent years, but there are still many areas of uncertainty and controversy in the field. One of the key challenges is the identification of additional cell-surface markers which accurately define a T reg -cell phenotype. This is a particular challenge in humans where the widely used Foxp3 transcription factor as a definitive marker for T reg -cells is less reliable than in the mouse. Several previous studies have addressed this issue [85, 86] and further clarification will greatly assist in the quantification and characterization of T reg -cell function ex vivo. Improvements in this area are likely to be crucial as subsequent studies attempt to more definitively establish the phenotype and function of T reg -cells in both health and disease. This point is well served by recent results from a study of human T reg -cells in patients with multiple sclerosis [87] . T reg -cells isolated by CD4 + CD25 hi expression had markedly impaired function ex vivo, but T reg -cells defined as CD4 + CD25 hi CD127 low had a similar regulatory function as cells from healthy individuals [87] .
In addition, it is important to acknowledge that the in vivo relevancy of the numerous in vitro T reg -cell assays which have been described and are widely used as a read-out of T reg -cell function remains unclear. Although this is likely to remain a problematic area in studies of human T reg -cell function, expanding in vitro analyses of T reg -cells beyond determining their capacity to suppress T-cell proliferation and cytokine production will be valuable. Future studies are also likely to focus on the mode of action of T reg -cells and their relative importance, a process which is likely to be greatly facilitated by studies of mutations limited to T reg -cell populations, such as the recently described investigation of T reg -cellspecific ablation of IL-10 [88] . As enthusiasm for the manipulation of T reg -cells in the clinical setting is likely to continue to grow, there are a wide range of challenges to overcome before this is likely to become a reality [89] . Initially, there is a clear need to further clarify the quantitative and qualitative status of T reg -cells in human disease since there is lack of an absolute consensus on this topic in many diseases as highlighted in the present review in the field of autoimmunity. However, if T reg -cells are to be used in the clinical setting then future studies are likely to focus on enhancing understanding as to how T reg -cells traffic to inflamed tissue and how the micro-environment within inflamed tissues influences their function. In addition, there is a need to increase our knowledge on effective expansion of T reg -cell in vitro strategies, development of antigen-specific T reg -cell therapy and establishing lifespan and stability of infused T reg -cells.
In summary, T reg -cells have become a dominant paradigm in our understanding of the maintenance of selftolerance. However, their role in the breakdown of tolerance and development of autoimmunity remains unclear; there are undoubtedly a large number of studies which have identified alterations in T reg -cell numbers or function in experimental models of autoimmunity and in patients with spontaneous disease. Nonetheless, there is also a wealth of data which has reported no evidence of a quantitative or qualitative decline in T reg -cells even at the site of disease. Consequently, there is much to be clarified in our understanding of the role of T reg -cells in autoimmunity and the examination of factors which may alter T reg -cell function at the site of disease may open up novel therapeutic avenues.
